CD46和雌激素受体在乳腺癌组织中的表达及临床意义

目的探讨CD46、雌激素受体（ER）在浸润性乳腺癌、乳腺良性肿瘤及正常乳腺组织中的表达水平及其对乳腺癌患者预后的临床意义。方法采用免疫组化的方法检测60例浸润性乳腺癌、60例乳腺良性肿瘤及30例正常乳腺组织标本CD46、ER的表达，并分析该表达与不同临床病理特征之间的关联性，以及采用生存分析CD46、ER的表达对患者预后的临床意义。结果乳腺癌组织CD拍阳性率（81．67％）明显高于乳腺良性肿瘤（58．33％）和正常乳腺组织（46．67％）；ER阳性率（50．00％）明显高于乳腺良性肿瘤（33．33％）和正常乳腺组织（26．67％），差别均有统计学意义（P〈0．05）；CD46表达阳性率与临床分级、肿瘤直径、有无淋巴结转移、血管浸润、TNM分期等呈正相关（P〈0．05）；ER表达阳性率与患者年龄、临床分级、肿瘤直径等呈正相关（P〈0．05）；CD46、ER阳性表达均可致患者的生存预后变差，浸润程度、有无淋巴结转移、临床分期、CD46、ER的表达是乳腺癌5年生存率独立的危险因素（P〈0．05）。结论CD46、ER阳性表达与更严重的乳腺癌病理特征相关，并对较差的预后具有提示作用。

Objective To analysis the expression and clinical significance of CD46, estrogen receptor （ ER ） in invasive breast cancer, benign breast tumors and normal breast tissues. Methods Immunohistochemistry was used to detect the expression of CD46 and ER in 60 cases invasive breast cancer, 60 cases benign breast tumor and 30 cases normal breast tissue samples, and to analyze relationships between the expression and clinicopathological characteristics and the clinical significance of CD46, ER expression. Results CD46-positive rate （ 81.67% ） of breast cancer was significantly higher than that of benign breast tumor （ 58.33% ） and normal breast tissue （ 46.67% ） ; ER-positive rate （ 50.00% ） was significantly higher than benign breast tumor （ 33.33% ） and normal breast organizations （ 26.67% ） （ P〈0.05 ） ; CD46 positive expression rate and clinical grade, tumor diameter, lymph node professional, vascular invasion, TNM stage and so has a positive correlation （ P〈0.05 ） ; ER expression was associated with age, clinical stage, tumor diameter, and so has a positive correlation （P〈0.05 ） ; the expressions CD46 and ER can be caused by poor survival prognosis, invasion, lymph node metastasis, clinical stage, the expressions of CD46 and ER were independent risk factors （P〈0.05 ） in breast cancer 5-year survival. Conclusion CD46, ER positive rate in more severe breast cancer is higher and is associated with poor prognosis.